Post-licensure safety of the meningococcal group C conjugate vaccine

Human Vaccines

Volumn 3, Issue 2, 2007, Pages 59-63

  Andrews, Nick ^a   Stowe, Julia ^a,b   Miller, Elizabeth ^a   Taylor, Brent ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Convulsions; ITP; Meningococcal group C conjugate vaccine; Purpura; Vaccine safety

Indexed keywords

DIPHTHERIA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MUMPS VACCINE; PERTUSSIS VACCINE; RUBELLA VACCINE; TETANUS TOXOID;

ANAPHYLACTOID PURPURA; ARTICLE; CHILD; CONFIDENCE INTERVAL; CONVULSION; FEMALE; HOSPITAL ADMISSION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LICENSING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PURPURA; SELF CONTROL; STATISTICAL ANALYSIS; UNITED KINGDOM; VACCINATION;

EID: 33947674137     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.2.3878     Document Type: Article

References (17)

1. Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993/4 to 2003/04; contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006; 55:887-96.
2. Miller E, Salisbury D, Ramsay M. Planning, registration, and the implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: A success story. Vaccine 2002; 20:558-67.
3. Southern J, Gelb O, Andrews N, Waight PA, Morris R, Cartwright K, Miller E. Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinations. Human Vaccines 2006; 2:237-42.
4. Miller E, Waight P, Farrington P. Safety assessment post-licensure. Dev Biol Scand 1998; 95:235-436.
5. st May 2002. Web reference: www.mhra.gov.uk/home/ groups/pl-p/documents/websiteresources/ con2022528.pdf, (Accessed January 15th 2007).
6. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 1995; 51:228-35.
7. Farrington P, Pugh S, Colville A, Flower A, Nash J, Morgan-Capner P, Rush M, Miller E. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps rubella vaccine. Lancet 1995; 345:567-9.
8. Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001; 84:227-9.
9. Vestergaard M, Hviid A, Madsen KM, Wohlfahrt J, Thorsen P, Schendel D, Melbye M, Olsen J. MMR vaccination and febrile seizures: Evaluation of susceptible subgroups and long-term prognosis. JAMA 2004; 292:351-7.
10. Miller E, Andrews N, Stowe J, Grant A, Waight P, Taylor B. The risk of convulsions and aseptic meningitis following MMR vaccination in the UK, Am J Epidemiol 2007; 165:704-9.
11. Abeyagunawardena AS, Goldblatt D, Andrews N, Trompeter RS. Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome. The Lancet 2003; 362:449-50.
12. Taylor B, Andrews N, Stowe J, Hamidi-Manesh L, Miller E. No increased risk of relapse after meningococcal C conjugate vaccine in childhood nephrotic syndrome. Archives of Disease in Childhood; In press.
13. CDC. Guillain-barre syndrome among recipients of menactra meningococcal conjugate vaccine-United states, June-July 2005. MMWR 2005; 54, (Oct 2005).
14. Miller E, Ashworth LAE, Redhead K, Thornton C, Waight PA, Coleman T. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: Value of laboratory tests as predictors of clinical performance. Vaccine 1997; 15:51-60.
15. Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B. Thiomersal exposure in infants and developmental disorders; A retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics 2004; 114:584-91.
16. Cano R, Larrauri A, Mateo S, Alcalá B, Salcedo C, EurosurveillanceVázquez JA. Impact of the meningococcal C conjugate vaccine in Spain: An epidemiological and microbiological decision. Eurosurveillance 2004; 9:11-5.
17. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal C conjugate vaccine 4 years after introduction. The Lancet 2006; 364:365-7.